Scholarlink

Backgrounds <p>Colorectal cancer (CRC) is one of the most common and fatal cancers worldwide, often diagnosed at advanced stages. Iron homeostasis, a crucial metabolic pathway in cancer, significantly impacts tumor progression.</p> Results <p>This study systematically investigated the function and significance of iron homeostasis-related genes (IHGs) in CRC, leading to the establishment of iron homeostasis-related molecular subtypes (IHMS) and a prognostic model based on their expression profiles of IHGs. Both IHMS and the model showed strong predictive accuracy for prognosis, clinical parameters, and response to immunotherapy. Patients classified as IHMS-B or exhibiting high model risk scores had poorer prognoses, while those categorized as IHMS-C or with low model risk scores were associated with more favorable outcomes and increased sensitivity to immunotherapy across multiple datasets. The model key gene HAMP (encoding hepcidin) was identified as a key oncogenic regulator that promotes CRC progression; elevated levels of HAMP/hepcidin were linked to peritoneal metastasis. Knocking out HAMP resulted in reduced tumor burden and inhibited proliferation and cancer stemness in both in vivo and in vitro models. Additionally, integration of in-house bulk-seq and tissue-array data further substantiated the clinical significance of HAMP/hepcidin and its association with immune landscapes.</p> Conclusions <p>In conclusion, both IHMS and the model serve as effective predictors for CRC prognosis and patient stratification. HAMP/hepcidin, a central regulator of iron homeostasis, plays a pivotal role in driving the progression and metastasis of CRC, underscoring the therapeutic potential of targeting the HAMP-mediated iron axis to improve clinical outcomes in CRC.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative genomic profiling of iron homeostasis predicts clinical outcomes and identifies HAMP/hepcidin as a therapeutic target in colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月31日

查看全文
  • Yanfei Shao,
  • Chaozhao Chen,
  • Xian Zhang,
  • Nanqin Liu,
  • Xiaodong Fan,
  • Xin Yi Tan,
  • Buyu Deng,
  • Ruitian Gao,
  • Songchang Shi,
  • Haoran Zhao,
  • Huang Zheng,
  • Cixiang Zhou,
  • Qianru Yu,
  • Xin Zhang,
  • Jiao Wang,
  • Joshua Lin,
  • Xueliang Zhou,
  • Yi Yang,
  • Yi Lu,
  • Batuer Aikemu,
  • Sen Zhang,
  • Qian Zhao,
  • Jing Sun

摘要

Backgrounds

Colorectal cancer (CRC) is one of the most common and fatal cancers worldwide, often diagnosed at advanced stages. Iron homeostasis, a crucial metabolic pathway in cancer, significantly impacts tumor progression.

Results

This study systematically investigated the function and significance of iron homeostasis-related genes (IHGs) in CRC, leading to the establishment of iron homeostasis-related molecular subtypes (IHMS) and a prognostic model based on their expression profiles of IHGs. Both IHMS and the model showed strong predictive accuracy for prognosis, clinical parameters, and response to immunotherapy. Patients classified as IHMS-B or exhibiting high model risk scores had poorer prognoses, while those categorized as IHMS-C or with low model risk scores were associated with more favorable outcomes and increased sensitivity to immunotherapy across multiple datasets. The model key gene HAMP (encoding hepcidin) was identified as a key oncogenic regulator that promotes CRC progression; elevated levels of HAMP/hepcidin were linked to peritoneal metastasis. Knocking out HAMP resulted in reduced tumor burden and inhibited proliferation and cancer stemness in both in vivo and in vitro models. Additionally, integration of in-house bulk-seq and tissue-array data further substantiated the clinical significance of HAMP/hepcidin and its association with immune landscapes.

Conclusions

In conclusion, both IHMS and the model serve as effective predictors for CRC prognosis and patient stratification. HAMP/hepcidin, a central regulator of iron homeostasis, plays a pivotal role in driving the progression and metastasis of CRC, underscoring the therapeutic potential of targeting the HAMP-mediated iron axis to improve clinical outcomes in CRC.

Graphical abstract